Tag:

Hepatitis C

Latest Headlines

Latest Headlines

England sets aside $31M to fund Sovaldi for sickest patients

While next-gen hep C treatment Sovaldi costs $84,000 per 12-week course of treatment, it boasts a 90% cure rate--and that's convinced the U.K.'s National Health Service to spend £18.7 million to fund the treatment for England's sickest patients.

AbbVie angles for hep C spotlight as Merck shoulders to the front

While AbbVie is widely expected to be the second entrant to the soon-to-explode market for hepatitis C cocktail drugs after standard-bearer Gilead Sciences, promising data from latecomer Merck have analysts relegating the Illinois company to third place despite some excellent late-stage results.

Bristol-Myers jockeys for promising position in hep C drug race

Three days after Bristol-Myers Squibb filed for FDA approval of the NS5A drug daclatasvir combined with asunaprevir, an NS3 protease inhibitor, the biotech company has turned over some of the Phase III cards it will be playing for an approval in markets around the world.

UPDATED: Watch out, Gilead. Merck is mounting a hep C combo comeback

Merck may be late to the blockbuster party with its new hepatitis C drugs, but the pharma giant is moving fast with a top contender boasting high cure rates.

Express Scripts adds fuel to the fire in fight over Gilead Sciences' Sovaldi

Express Scripts released more stunning numbers on what could happen with spending on drugs to treat hepatitis C as it builds a case against the price Gilead Sciences has put on a drug that can cure the disease.

Low-profile Alios gets a roster of Big Pharma funds to back anti-RSV therapy

Even after out-licensing a pair of hepatitis C therapeutic candidates to Vertex, which was bidding on finding a contender as a new wave of transformational drugs approached the market, South San Francisco-based Alios BioPharma stubbornly maintained a very low profile.

Express Scripts assembling anti-Sovaldi coalition to shut out Gilead hep C drug

Express Scripts and Gilead Sciences are playing a high-priced game of chicken. At stake is the fate of Sovaldi (sofosbuvir), Gilead's high-priced hepatitis C pill, and the future of hep C treatment in the U.S. Not to mention the future of Sovaldi rivals from AbbVie, Bristol-Myers Squibb, and more.

Gilead's Sovaldi triumph puts major hurt on payers' bottom lines

Hepatitis C wonder-drug Sovaldi is still selling at breakneck pace. And at this rate, it could break some insurers. At $84,000 per 12-week treatment course, Sovaldi's quick uptake is threatening payers' earnings, analysts say--and the drug's stellar efficacy profile leaves them with few options.

Merck's new PhIII hep C program may help repair a damaged R&D rep

In a matter of weeks Merck plans to move a closely-watched combination treatment for hepatitis C into a Phase III trial. The move will boost Merck's late-stage pipeline to 13 programs, giving new R&D chief Roger Perlmutter some additional evidence to back up a case that the leviathan outfit has finally shaken off the lethargy that led to a years-long drought of significant approvals, focusing on pioneering therapies that can carve out badly needed revenue.

Politicians add fuel to the firestorm over Gilead's hep C drug pricing

Rep. Henry Waxman and several Democratic colleagues in Congress wrote Gilead CEO John Martin an excoriating letter on Friday, demanding to know why Gilead Sciences' hepatitis C wonder drug Sovaldi costs $84,000--and whether Gilead is doing anything to make sure that poor patients get access to it.